GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » US-China Biomedical Technology Inc (GREY:UCBB) » Definitions » Shares Outstanding (EOP)

UCBB (US-China Biomedical Technology) Shares Outstanding (EOP) : 19.80 Mil (As of May. 2019)


View and export this data going back to 2011. Start your Free Trial

What is US-China Biomedical Technology Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. US-China Biomedical Technology's shares outstanding for the quarter that ended in May. 2019 was 19.80 Mil.

US-China Biomedical Technology's quarterly shares outstanding increased from Feb. 2019 (15.51 Mil) to May. 2019 (19.80 Mil). It means US-China Biomedical Technology issued new shares from Feb. 2019 to May. 2019 .

US-China Biomedical Technology's annual shares outstanding increased from Feb. 2018 (13.51 Mil) to Feb. 2019 (15.51 Mil). It means US-China Biomedical Technology issued new shares from Feb. 2018 to Feb. 2019 .


US-China Biomedical Technology Shares Outstanding (EOP) Historical Data

The historical data trend for US-China Biomedical Technology's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

US-China Biomedical Technology Shares Outstanding (EOP) Chart

US-China Biomedical Technology Annual Data
Trend Feb12 Feb13 Feb14 Feb15 Feb16 Feb17 Feb18 Feb19
Shares Outstanding (EOP)
Get a 7-Day Free Trial 13.03 13.03 13.03 13.51 15.51

US-China Biomedical Technology Quarterly Data
Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Aug16 Nov16 Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Feb19 May19
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.51 15.51 15.51 15.51 19.80

Competitive Comparison of US-China Biomedical Technology's Shares Outstanding (EOP)

For the Health Information Services subindustry, US-China Biomedical Technology's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


US-China Biomedical Technology's Shares Outstanding (EOP) Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, US-China Biomedical Technology's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where US-China Biomedical Technology's Shares Outstanding (EOP) falls into.



US-China Biomedical Technology Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


US-China Biomedical Technology  (GREY:UCBB) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


US-China Biomedical Technology Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of US-China Biomedical Technology's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


US-China Biomedical Technology Business Description

Traded in Other Exchanges
N/A
Address
2 Park Plaza, Suite 400, Irvine, CA, USA, 92614
US-China Biomedical Technology Inc is an early stage biomedical technology and services company. It is engaged in the integration and development of synergistic relationships with high profiled doctors and hospitals that will act as a bridge for connecting patients and bio-technology advances in China with its network of US based doctors and hospitals. It provides services for moving patients from China to the US with an emphasis on the demographics including pre-screening and genetic testing for family members of cancer patients, patients suffering from Diabetes, and general medical services including preventative care and physicals.

US-China Biomedical Technology Headlines

No Headlines